NEO

NeoGenomics, Inc. (NEO) | Rumor.io

NeoGenomics

NEO

Attention (50-day avg)0%

Attention rank (50-day avg)#1,715

Bullish sentiment (50-day avg)100%

Price to earnings ratio-23

Market capitalization2.5B

Earnings per share-0.39

Dividend yield (TTM)—

Revenue (annual)727.3M

Net income (annual)-108M

Social

What share of all stock conversation is about NEO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Apr 29

NeoGenomics, Inc. (NEO) reported solid revenue growth and strategic product launches in Q1 2026, with a positive outlook for the remainder of the year.
Benchmark and Leerink Partners upgraded NeoGenomics to "buy" and raised their target price to $25.00, citing better-than-expected sales results and raised FY26 sales guidance.
NeoGenomics shares were trading lower, down -8.5% to $8.26, with 6.2M shares traded, despite the positive earnings report and analyst upgrades.

Generated by AI

Sentiment

Of the messages about NEO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.2% +13.36
Bearish	—	—	—	6.8% -13.36

Bullish· Aug 29

$NEO is poised for growth after a court win vs. $NTRA, which invalidated key patent claims, clearing the path for RaDaR ST cancer detection test rollout and potential CMS reimbursement approval.
Options scarcity in $NEO is leading to a classic squeeze, with GreetEat Corp bids upticking while asks thin out, indicating a strong demand for the stock.
$NEO's Q2 2025 revenue growth, driven by cancer diagnostics, has boosted the stock, and the August 29, 2025 patent victory has eliminated a major business threat and unlocked significant growth opportunities.

Bearish· Apr 29

$NEO's 32% drop is unjustified according to the company's recent earnings call.
The stock's high trading volume on the day of the drop suggests a large-scale sell-off.
The company's CEO turnover and declining revenue may be contributing to its poor market performance.

Generated by AI

Topics

Of the messages about NEO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	82.39%
Analysts	—	—	—	1.31%
Controversies	—	—	—	0.33%
Earnings	—	—	—	1.2%
Macro	—	—	—	7.22%
Technical Analysis	—	—	—	7.55%

Analysts· Mar 29

NeoGenomics' CEO has departed, and analysts are reevaluating the company's stock, with some maintaining an "Outperform" rating and lowering price targets.
Analysts' average price target for NeoGenomics is $26.25, with some individual targets ranging from $19 to $28, implying potential upside from the current price of $17.79.
A majority of analysts (85%) maintain a "Buy" consensus on NeoGenomics, with some analysts downgrading the stock to "Neutral" or "Equal-Weight" and lowering price targets.

Announcements· Aug 29

NeoGenomics (NEO) wins patent lawsuit against Natera, with the court ruling Natera's patents invalid for claiming ineligible subject matter.
The court victory clears the path for NeoGenomics to commercialize its RaDaR ST molecular residual disease (MRD) assay in the US, potentially unlocking significant growth opportunities.
The patent win is expected to eliminate a major business threat for NeoGenomics and strengthen its competitive position in the molecular residual disease testing market.

Generated by AI

Community

Of the messages about NEO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	13.79%
Newcomers	—	—	100%	86.21%

Regulars· Apr 29

NeoGenomics' non-GAAP EPS beat expectations, but revenue missed by $2.86M, coming in at $168.04M.
The company's first quarter 2025 results were reported, with earnings beating estimates but revenue falling short.
Analysts from BofA and other firms see the euro gaining against the US dollar, with NeoGenomics' stock price potentially impacted.

Newcomers· Feb 28

New investors are considering forming a position in $NEO, potentially benefiting from upcoming market developments.
The post highlights the importance of being aware of market information and not getting swept away by it.
The author is cautious about the current market situation and suggests being prepared for potential changes.

Generated by AI

NeoGenomics stock reaction to precision oncology expansion plan NeoGenomics (NEO) drew investor attention after executives detailed plans to expand in community-based precision oncology, highlighting next-generation sequencing, minimal residual disease testing, and workflow tools for community physicians as key focus areas. NeoGenomics shares have been on a strong run recently, with a 30-day share price return of 14.31% and a 90-day gain of 69.22%. The 1-year total shareholder return of...

8d agoYahoo Finance

Is NeoGenomics’ (NEO) Community NGS Push Quietly Redefining Its Core Earnings Engine?

Earlier in 2026, NeoGenomics executives detailed plans to expand in community-based precision oncology, with a particular push into next-generation sequencing, minimal residual disease testing, and workflow tools for community oncologists. An important takeaway is that NGS already represents a relatively small share of test volume but a much larger portion of clinical revenue, underscoring how mix shift toward advanced assays could reshape the company’s earnings profile. We’ll now examine...

8d agoYahoo Finance Singapore

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at t

9d agoYahoo Finance

Neogenomics stock hits 52-week high at 19.78 USD

12d agoInvesting.com

NeoGenomics at Morgan Stanley conference: NGS, MRD drive growth

14d agoInvesting.com

A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and its peers.

18d agoYahoo Finance

Also Discussed

Investors talking about NEO also mention

#	Name	Attention
1	NeoNEO	0%new
2	GasGAS	0.02%-0.02
3	LTC Properties, Inc.LTC	0%0
4	OntologyONT	0%0
5	Moody's CorporationMCO	0%0
6	LeMaitre Vascular Inc.LMAT	0%0
7	ICONICX	0%new
8	Trx Gold Corp.TRX	0%new
9	Boise Cascade CompanyBCC	0%0
10	FLM - First Trust Alerian U.S. NextGen Infrastructure ETF	——

NeoGenomics, Inc.

Healthcare
Diagnostics & Research

NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, and pathology support. Its services are used by oncologists, pathologists, hospitals, academic medical centers, and pharmaceutical companies to help characterize disease, guide treatment decisions, and support clinical research and drug development. NeoGenomics operates a network of cancer-focused laboratories in the United States and the United Kingdom, with business operations organized around Clinical Services and Advanced Diagnostics. Headquartered in Fort Myers, Florida, NeoGenomics plays a specialized role in precision medicine by delivering laboratory data and expert interpretation for cancer diagnosis and care.

Website

Location

9490 NeoGenomics Way

Fort Myers, FL, 33912

United States

Social

What share of all stock conversation is about NEO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Apr 29

NeoGenomics, Inc. (NEO) reported solid revenue growth and strategic product launches in Q1 2026, with a positive outlook for the remainder of the year.
Benchmark and Leerink Partners upgraded NeoGenomics to "buy" and raised their target price to $25.00, citing better-than-expected sales results and raised FY26 sales guidance.
NeoGenomics shares were trading lower, down -8.5% to $8.26, with 6.2M shares traded, despite the positive earnings report and analyst upgrades.

Generated by AI

Sentiment

Of the messages about NEO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.2% +13.36
Bearish	—	—	—	6.8% -13.36

Bullish· Aug 29

$NEO is poised for growth after a court win vs. $NTRA, which invalidated key patent claims, clearing the path for RaDaR ST cancer detection test rollout and potential CMS reimbursement approval.
Options scarcity in $NEO is leading to a classic squeeze, with GreetEat Corp bids upticking while asks thin out, indicating a strong demand for the stock.
$NEO's Q2 2025 revenue growth, driven by cancer diagnostics, has boosted the stock, and the August 29, 2025 patent victory has eliminated a major business threat and unlocked significant growth opportunities.

Bearish· Apr 29

$NEO's 32% drop is unjustified according to the company's recent earnings call.
The stock's high trading volume on the day of the drop suggests a large-scale sell-off.
The company's CEO turnover and declining revenue may be contributing to its poor market performance.

Generated by AI

Topics

Of the messages about NEO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	82.39%
Analysts	—	—	—	1.31%
Controversies	—	—	—	0.33%
Earnings	—	—	—	1.2%
Macro	—	—	—	7.22%
Technical Analysis	—	—	—	7.55%

Analysts· Mar 29

NeoGenomics' CEO has departed, and analysts are reevaluating the company's stock, with some maintaining an "Outperform" rating and lowering price targets.
Analysts' average price target for NeoGenomics is $26.25, with some individual targets ranging from $19 to $28, implying potential upside from the current price of $17.79.
A majority of analysts (85%) maintain a "Buy" consensus on NeoGenomics, with some analysts downgrading the stock to "Neutral" or "Equal-Weight" and lowering price targets.

Announcements· Aug 29

NeoGenomics (NEO) wins patent lawsuit against Natera, with the court ruling Natera's patents invalid for claiming ineligible subject matter.
The court victory clears the path for NeoGenomics to commercialize its RaDaR ST molecular residual disease (MRD) assay in the US, potentially unlocking significant growth opportunities.
The patent win is expected to eliminate a major business threat for NeoGenomics and strengthen its competitive position in the molecular residual disease testing market.

Generated by AI

Community

Of the messages about NEO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	13.79%
Newcomers	—	—	100%	86.21%

Regulars· Apr 29

NeoGenomics' non-GAAP EPS beat expectations, but revenue missed by $2.86M, coming in at $168.04M.
The company's first quarter 2025 results were reported, with earnings beating estimates but revenue falling short.
Analysts from BofA and other firms see the euro gaining against the US dollar, with NeoGenomics' stock price potentially impacted.

Newcomers· Feb 28

New investors are considering forming a position in $NEO, potentially benefiting from upcoming market developments.
The post highlights the importance of being aware of market information and not getting swept away by it.
The author is cautious about the current market situation and suggests being prepared for potential changes.

Generated by AI

NeoGenomics

Social

Apr 29

Bullish· Aug 29

Bearish· Apr 29

Analysts· Mar 29

Announcements· Aug 29

Regulars· Apr 29

Newcomers· Feb 28

NeoGenomics (NEO) Expands Precision Oncology Focus, Is The Stock Fairly Valued?

Is NeoGenomics’ (NEO) Community NGS Push Quietly Redefining Its Core Earnings Engine?

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

Neogenomics stock hits 52-week high at 19.78 USD

NeoGenomics at Morgan Stanley conference: NGS, MRD drive growth

A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

Also Discussed

NeoGenomics, Inc.

Company Information

Location

NeoGenomics (NEO) Expands Precision Oncology Focus, Is The Stock Fairly Valued?

Is NeoGenomics’ (NEO) Community NGS Push Quietly Redefining Its Core Earnings Engine?

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

Neogenomics stock hits 52-week high at 19.78 USD

NeoGenomics at Morgan Stanley conference: NGS, MRD drive growth

A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

Also Discussed

Social

Apr 29

Bullish· Aug 29

Bearish· Apr 29

Analysts· Mar 29

Announcements· Aug 29

Regulars· Apr 29

Newcomers· Feb 28